Overview
Cxld. The Emerging Role of the Gut Microbiome in Reducing Recurrence of C. difficile Infection
Complimentary Lunch Symposium
Registration is closed for this activity.
Our multispecialty panel of internal medicine and gastroenterology faculty will discuss the changing epidemiology, diagnosis, and recurrence of C. difficile. In order to improve outcomes and minimize recurrence, knowledge and recognition must increase across clinicians and healthcare teams. This expert panel will review risk factors for C. difficile and its recurrence, the diagnosis, when referral may be necessary, and emerging therapies that restore gut microbiome.
This event is not part of the official Internal Medicine Meeting 2020 Education Program.
This event is not part of the official Internal Medicine Meeting 2020 Education Program.
This activity is intended for internal medicine physicians and other clinicians who care for patients at risk of serious infection.
The epidemiology of C. difficile has changed with a higher number of community-acquired cases that may be seen outside of hospital settings. Recurrence of C. difficile also continues to pose a significant burden on patients, clinicians, and the healthcare system despite some progress. Clinicians must be familiar with risk factors across diverse patient populations to select appropriate therapy to reduce recurrence. Novel approaches, such as microbiome restoration therapy, are also under investigation, and clinicians must be familiar with these emerging treatments aimed at reducing recurrence and improving clinical outcome.
Upon completion of this activity, participants will be able to:
• Evaluate the role of the gut microbiome in relationship to C difficile infection and approaches to restoration for prevention of recurrent infection
• Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Review guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
• Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
• Evaluate the role of the gut microbiome in relationship to C difficile infection and approaches to restoration for prevention of recurrent infection
• Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Review guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
• Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
Los Angeles Convention Center
1201 South Figueroa Street
Los Angeles, CA 90015 USA
Click here to view location map
1201 South Figueroa Street
Los Angeles, CA 90015 USA
Click here to view location map
12:00 PM - 12:15 PM
Registration and Lunch
12:15 PM - 12:25 PM
The Changing Epidemiology and Diagnosis of C. difficile
12:25 PM - 12:45 PM
The Evolution of Treatment for C. difficile and Recurrent Disease
12:45 PM -1:05 PM
Breaking the Cycle of Recurrence: Available and Emerging Approaches Beyond Antibiotic Therapy
1:05 PM - 1:15 PM
Panel Discussion and Q&A
Registration and Lunch
12:15 PM - 12:25 PM
The Changing Epidemiology and Diagnosis of C. difficile
12:25 PM - 12:45 PM
The Evolution of Treatment for C. difficile and Recurrent Disease
12:45 PM -1:05 PM
Breaking the Cycle of Recurrence: Available and Emerging Approaches Beyond Antibiotic Therapy
1:05 PM - 1:15 PM
Panel Discussion and Q&A
Supported by an educational grant from Ferring Pharmaceuticals Inc.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
To receive credit, participants are required to participate in the live activity and complete the posttest, and evaluation and submit on-site. A certificate will be emailed to participants within 6 weeks. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 205.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
